CureApp, Inc. is a Japanese digital health therapeutic medical device (software) company that was founded in 2014. Their slogan, "A new future of medical treatment with mobile applications," underscores their commitment to revolutionizing medical treatment through modern technology.
Specializing in the delivery of "Digital Therapeutics," CureApp, Inc. is focused on providing personalized DTx as a prescription choice, highlighting their emphasis on individualized and evidence-based solutions for medical treatment.
As a pioneering force in the industry, CureApp, Inc. aims to optimize medical treatment by leveraging robust scientific evidence and innovative digital solutions. Their dedication to integrating mobile applications with medical treatment exemplifies their forward-thinking approach.
While information about their last investment and investors is currently unavailable, CureApp, Inc. continues to position itself as a frontrunner in the digital health and medical device sector, with their headquarters based in Japan. Their commitment to advancing medical treatment through technology makes them a company to watch in the evolving landscape of healthcare innovation.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series G | ¥7.00B | 1 | 16 Aug 2022 | |
Series D | ¥2.10B | 10 | SIIF, Shinsei Bank +1 | 12 Mar 2021 |
Series C | ¥2.20B | 4 | KOSHIDAKA HOLDINGS, Intage Group | 05 Jul 2019 |
Series B | ¥1.50B | 10 | Saison Ventures, Iwagin Jigyo Souzou Capital +1 | 27 Feb 2018 |
Series A | ¥380.00M | 3 | 08 Feb 2017 |
No recent news or press coverage available for CureApp, Inc..